PTC logo PTC +
PTC
+

PTC (PTC) Business News

Track PTC in real time with a live news feed covering PTC stock news, official press releases, company announcements, and an archive of historical PTC news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
12:36 PM | Thursday | Nov 5, 2026 Zacks Investment Research

PTC Q4 Earnings & Revenues Beat Estimates, ARR Growth Strong

News Thumbnail
8:14 AM | Wednesday | Nov 4, 2026 GlobeNewsWire

INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – OPCH, PTC, RXO and SYNA - IS IT A FAIR DEAL FOR YOU?

News Thumbnail
12:22 PM | Tuesday | Nov 3, 2026 PRNewsWire

INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - OPCH, PTC, RXO and SYNA - IS IT A FAIR DEAL FOR YOU?

News Thumbnail
11:31 AM | Tuesday | Nov 3, 2026 Seeking Alpha

PTC Therapeutics: Sephience Keeps Beating The Forecast, But The Price Already Knows

News Thumbnail
7:00 AM | Tuesday | Nov 3, 2026 PRNewsWire

PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program

News Thumbnail
9:15 AM | Monday | Nov 2, 2026 Zacks Investment Research

PTC Heads Into Q4 Earnings as Schneider Buyout Looms: What's in Store?

News Thumbnail
8:00 AM | Monday | Nov 2, 2026 PRNewsWire

PTC Therapeutics to Participate in Upcoming Investor Conferences

News Thumbnail
9:36 AM | Friday | Oct 30, 2026 GlobeNewsWire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)

News Thumbnail
8:00 AM | Friday | Oct 30, 2026 GlobeNewsWire

Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study

News Thumbnail
11:05 AM | Thursday | Oct 29, 2026 Seeking Alpha

Parnassus Mid Cap Growth Fund: Q3 2026 Performance Review

News Thumbnail

PTC Q4 Earnings & Revenues Beat Estimates, ARR Growth Strong

Zacks Investment Research

12:36 PM | Thursday | Nov 5, 2026

news photo
Loading...

PTC's Q4 fiscal 2026 earnings and revenues beat estimates, while ARR growth remain strong despite revenue declines and divestiture-related pressures.

Read full article redirect
12:36 PM | Thursday | Nov 5, 2026

PTC Q4 Earnings & Revenues Beat Estimates, ARR Growth Strong

Zacks Investment Research

PTC's Q4 fiscal 2026 earnings and revenues beat estimates, while ARR growth remain strong despite revenue declines and divestiture-related pressures.

Read full article arrow
News Thumbnail
8:14 AM | Wednesday | Nov 4, 2026

INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – OPCH, PTC, RXO and SYNA - IS IT A FAIR DEAL FOR YOU?

GlobeNewsWire

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered on the 47th floor in the Empire State Building in New York City and are investigating if below deal is fair:

Read full article arrow
News Thumbnail
12:22 PM | Tuesday | Nov 3, 2026

INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - OPCH, PTC, RXO and SYNA - IS IT A FAIR DEAL FOR YOU?

PRNewsWire

/PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for

Read full article arrow
News Thumbnail
11:31 AM | Tuesday | Nov 3, 2026

PTC Therapeutics: Sephience Keeps Beating The Forecast, But The Price Already Knows

Seeking Alpha

PTC Therapeutics (PTCT) is rated Hold, bordering on Sell, with fair value estimated at $52/share versus a $59.97 current price. Sephience's strong launch drives growth, but legacy product declines offset gains; Q4 and 2027 results are key inflection points. PTCT's guidance has been consistently conservative, with actual quarterly sales repeatedly beating top-end forecasts.

Read full article arrow
News Thumbnail
7:00 AM | Tuesday | Nov 3, 2026

PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program

PRNewsWire

WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of the Company's outstanding shares of common stock, subject to market conditions.

Read full article arrow
News Thumbnail
9:15 AM | Monday | Nov 2, 2026

PTC Heads Into Q4 Earnings as Schneider Buyout Looms: What's in Store?

Zacks Investment Research

PTC's fiscal Q4 results hinge on ARR growth, AI adoption and cash flow momentum, while its pending $22.6 billion acquisition by Schneider Electric adds a key dimension.

Read full article arrow
News Thumbnail
8:00 AM | Monday | Nov 2, 2026

PTC Therapeutics to Participate in Upcoming Investor Conferences

PRNewsWire

WARREN, N.J., Nov. 2, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Jefferies Global Healthcare Conference  Monday, Nov.
16 at 11 a.m.

Read full article arrow
News Thumbnail
9:36 AM | Friday | Oct 30, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)

GlobeNewsWire

BALA CYNWYD, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.
com) at 855-576-4847. There is no cost or financial obligation to you.

Read full article arrow
News Thumbnail
8:00 AM | Friday | Oct 30, 2026

Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study

GlobeNewsWire

Interim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos's R&D Facility; Data Support IND-Enabling Development Ahead of Planned First-in-Human Trials

Read full article arrow
News Thumbnail
11:05 AM | Thursday | Oct 29, 2026

Parnassus Mid Cap Growth Fund: Q3 2026 Performance Review

Seeking Alpha

The portfolio's outperformance was primarily driven by our holdings in the Health Care sector, which delivered strong returns for the quarter on company-specific catalysts. Information Technology holdings and underweight to the Energy sector detracted from returns. For the year-to-date period, the Fund returned 5.80% (net of fees), outperforming the Russell Midcap Growth Index's 1.01%.

Read full article arrow
News Thumbnail